Relebactam

Relebactam
Clinical data
Other names	MK-7655
Legal status
Legal status	US: ℞-only;
Identifiers
	IUPAC name [(2S,5R)-7-Oxo-2-(piperidin-4-ylcarbamoyl)-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate;
CAS Number	1174018-99-5;
PubChem CID	44129647;
DrugBank	DB12377;
ChemSpider	31137585;
UNII	1OQF7TT3PF;
Chemical and physical data
Formula	C12H20N4O6S
Molar mass	348.37 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)NC3CCNCC3;
	InChI InChI=1S/C12H20N4O6S/c17-11(14-8-3-5-13-6-4-8)10-2-1-9-7-15(10)12(18)16(9)22-23(19,20)21/h8-10,13H,1-7H2,(H,14,17)(H,19,20,21)/t9-,10+/m1/s1; Key:SMOBCLHAZXOKDQ-ZJUUUORDSA-N;

Relebactam is a chemical compound used in combination with antibiotics to improve their efficacy. As a beta-lactamase inhibitor, it blocks the ability of bacteria to break down a beta-lactam antibiotic. In the United States, relebactam is approved for use in the combination imipenem/cilastatin/relebactam (Recarbrio by Merck).